Viewing nowLicast Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
(Co., Ltd.) Theragen Etex

MFDS item code 201601187 · Approved 2016.02.29 · Insurance code 698503400
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to effectively treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures in epilepsy patients, either with or without secondary generalized symptoms. Additionally, it helps in the treatment of fibromyalgia. Therefore, this drug is widely used for various neurological disorders and pain management.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Because the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may cause mental health issues such as suicidal impulses or behaviors, so patients must be closely monitored for mood changes or abnormal behaviors while taking it. Patients with hypersensitivity to this drug should not use it. Diabetic patients may experience weight gain while taking this drug and may need to adjust the dosage of blood glucose controlling medications. If allergic reactions, such as angioedema, occur, discontinue this medication immediately. Elderly patients should take special care at the beginning of treatment due to increased dizziness and drowsiness, as there is a risk of falls or injuries. This medication may cause visual disturbances such as blurred vision; consult a doctor if symptoms occur. Abrupt discontinuation can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so dosage should be gradually reduced under physician guidance. Due to the risk of drug abuse, patients with a history of substance abuse should use this medication cautiously and be monitored for signs of misuse. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should be cautious when taking this drug as it may increase the risk of heart failure. Concurrent use with central nervous system depressants or opioid analgesics may increase the risk of respiratory depression; caution is advised during co-administration. During early pregnancy, there may be a risk of fetal deformities, so it should not be used unless necessary, and women of childbearing age should use effective contraception. Breastfeeding women should consult a doctor as this drug may be transmitted through breast milk, potentially requiring them to stop breastfeeding. This drug may cause dizziness and drowsiness; caution is needed while driving or operating hazardous machinery. Severe skin reactions may occur rarely, so if unusual symptoms such as skin rashes or swelling appear, stop taking the medication immediately and consult healthcare providers. In case of overdose, symptoms may include altered consciousness, drowsiness, and depression; seek immediate medical attention, and renal replacement therapy such as dialysis may be required.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 15 to 30 degrees Celsius. This helps maintain the medication's effectiveness for a longer period.
A hard capsule with a reddish-brown upper and white lower part containing white powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
(Co., Ltd.) Theragen Etex

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.